Jakavi 15mg tablets |Ruxolitinib | MHP

-

JAKAVI 15MG

DESCRIPTION

Jakavi 15mg belongs to the classification of medications called anti-cancer drugs.
Jakavi 15mg tablet is a Janus kinase inhibitor with discrimination for subtypes JAK1 and JAK2 of this enzyme. Jakavi 15mg prohibits dysregulated JAK signaling along with myelofibrosis. This regimen is not prescribed for use in patients below 18 years of age.
Jakavi 15mg tablet is prescription drug provided under supervision of medical oncologist.
jakavi 15mg tablet
JAKAVI 15MG


MECHANISM OF ACTION

Ruxolitinib is also known as targeted treatment which targets and joints to the tyrosine kinase receptors and prohibits Janus Associated Kinases (JAK1 and JAK2) which Intercede the signaling of several cytokines and growth factors which are important for hematopoiesis and immune function. By irrevocable to these receptors, Ruxolitinib stops important pathways which develop cell division. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be analogue with dysregulated JAK1 and JAK2 signaling. Patients with MF who either carry the JAK2 V617 mutation or does not have the JAK2 V617F mutation may both respond to Ruxolitinib.

PRODUCT DETAILS

Brand :Jakavi
Ingredients : Ruxolitinib
Strength : 15mg
Manufactured : Novartis Ltd
Package : Strips of 14 tablets

ADME

Absorption:
Rapid absorption and not affected by food maximum plasma level is 1.5 hours.
Distribution:
Volume of distribution is 76.6 L plasma protein binding is 97%
Metabolism:
metabolized by CYP3A4
Elimination:
Excreted via urine 74% and unchanged drug is <1% and through urine 22%, <1 % as unchanged drug

DOSAGE MANAGEMENT

Myelofibrosis :
Starting recommended doses for myelofibrosis
If Platelet count >200 x10^9/L the prescribed dose is 20 mg PO BID
If Platelet count 100-200 x10^9/L the prescribed dose is 15 mg PO BID
If Platelet count 50 to <100 x10^9/L the prescribed dose is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID
Polycythemia Vera :
The prescribed dose is 10mg PO BID
Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.

PRECAUTIONS

Progressive multifocal leukoencephalopathy (PML) has occurred with Jakavi 15mg treatment. If PML is suspected, discontinue Jakavi 15mg tablet and evaluate.
Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have resulted in patients administrated with Jakavi 15mg. Do the periodic skin examinations.
Therapy with Jakavi 15mg can resulted in thrombocytopenia, Anemia and neutropenia. Regulate thrombocytopenia by decreasing the dose or temporarily prohibit Jakavi 15mg. Platelet transfusions may be needed.
Risk of infection occurs by delay initiate treatment with Jakavi 15mg tablet until active serious infection have resolved.
Tuberculosis infection has been resulted in patients administrating Jakavi 15mg. monitor patients getting Jakavi 15mg tablet for signs and symptoms of active tuberculosis and manage promptly.

SIDE EFFECTS

• Cholesterol level increased
• Dyspnea
• Nasopharyngitis
• Headache
• Constipation
• Decreased RBC
• Reduce in platelet counts
• Nausea & Vomiting
• Sleeplessness
• Liver enzymes increased
• Diarrhea
• bleeding
• Swelling
• Neutropenia
• Dizziness

PREGNANCY

The drug has no studies with the Jakavi 15mg use in pregnant women to inform drug-along with risks. Hence avoid becoming pregnancy during Jakavi 15mg treatment

LACTATION

Avoid breastfeeding to infants during treatment with Jakavi 15mg tablet. Excretion into human milk is unknown

STORAGE

Jakavi 15mg stored at 20°C to 25°C
Protect away from light and moisture
Dispense in its original container

CONTACT DETAILS

EMAIL:          millionhealthpharmaceuticals@gmail.com

PHONE NO:+91-9940472902

WEBSITE:    https://millionpharma.com/jakavi-15mg.php



Comments

Post a Comment

Popular posts from this blog

Biceltis 440mg | Lapatinib | MHP

-
Image
BICELTIS 440MG DESCRIPTION Biceltis 440mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology. Biceltis 440mg helps to decrease the rate of reactivation & mortality. One of the epidermal growth factor receptors is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer. This factor is responsible for cell replication. An FDA approved product Biceltis 440mg which is involved in breast cancer treatment. Biceltis 440mg vial with 858mg of lyophilized powder containing 440mg of Trastuzumab. gastri cancer breast cancer INDICATION The drug Biceltis 440mg injection is used for the treatment of Supportive treatment for breast cancer The drug Biceltis 440mg injection is used for the treatment of Advanced breast cancer The drug Biceltis 440mg injection is used for the treatment of Advanced gastric
Read more

Tasigna 150mg - Anticancer drugs | view uses, side effects and price | MHP

-
Image
NILOTINIB 150MG DESCRIPTION Nilotinib sold under the brand name Tasigna 150mg tablet and its belongs to targeted cancer cells Tasigna is anticancer drugs, which prohibits development of the cancer cells. Tasigna 150mg  is a prescription medicine, which sold under the supervision of medical oncologist. Tasigna 150mg is also belongs to the class of kinase inhibitors. tasigna 150mg TASIGNA INDICATION Tasigna 150mg tablets is mainly indicated in the conditions like; Chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included Imatinib in adult patients MECHANISM OF ACTION CML: chronic myelogenous leukemia is caused by BCR-ABL oncogene Tasigna 150mg (nilotinib) is a kinase inhibitor, which prohibits BCR-ABL kinase activity. Tasigna 150mg tablet link to the ATP-bounding site of BCR-ABL protein Tasigna 150mg inhibits proliferation of murine leukemic cell lines and human ce
Read more

Alecensa 150mg | Alectinib | MHP

-
Image
ALECENSA 150MG DESCRIPTION Alecensa 150mg consist of second-generation anaplastic lymphoma kinase (ALK) inhibitor authorized by the US Food and Drug Administration to cure crizotinib-refractory non-small cell lung cancer Alecensa 150mg capsule inhibits the developments of cancer cells which are then damaged by the body Alecensa 150mg which is used asprescription drug under the supervision of medical oncologist. alecensa 150mg INDICATION Alecensa 150mg capsule is prescribed for the therapy in patientsaffected by anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). MECHANISM OF ACTION ALK is a family of proteins known as receptor tyrosine kinases (RTKs), which are included in the growth of cells and the development of new blood vessels which supply them. In patients with ALK-positive NSCLC, an abnormal form of ALK is formedwhichencourage the cancer cells to multiply and grow in an uncontrolled fashion. The active substance in Alecti
Read more